Lupin launches generic Xenazine
Lupin is introducing its generic Xenazine tablets (tetrabenazine). The generic Valeant Pharmaceuticals drug, which will be available in 12.5- and 25-mg dosage strengths, was previously approved by the Food and Drug Administration.
The product is indicated for the treatment of chorea associated with Huntington’s disease.
Xenazine tablets had a market value of $153 million, according to IQVIA September 2018 data.
The product is indicated for the treatment of chorea associated with Huntington’s disease.
Xenazine tablets had a market value of $153 million, according to IQVIA September 2018 data.